Delpor

Delpor is a clinical-stage biopharmaceutical company utilizing innovative technologies to develop once-a-year therapies for chronic conditions. The company’s lead product is a 6-12 month formulation of risperidone for the treatment of schizophrenia. Delpor is also pursuing 6-12 month formulations of other drugs targeting central nervous system disorders, including schizophrenia, addiction, spasticity, Parkinson’s disease, Alzheimer’s disease, and other conditions.